头颈肿瘤门诊实施部位特异性患者报告结局量表的可行性与可接受性:一项前瞻性机构研究
本研究在2020年9月至2021年8月于三级癌症机构前瞻性纳入新诊断头颈肿瘤放疗患者,评估MDASI-HN模块在放疗科实施的可行性与可接受性。实施后队列51例,29例(60%)完成退出调查;89%患者认为MDASI-HN更容易记住症状,86%推荐常规使用;5名头颈放疗提供者中4名(80%)回应,75%认为提供临床相关信息、改善沟通且未增加门诊时间。患者报告体验总体未受影响(P=0.82),实施后队列在门诊协调领域正面回应概率随时间显著(P=0.025)。
要点
- 89%患者认为MDASI-HN更容易记住症状,86%推荐常规使用。
- 75%提供者认为MDASI-HN提供临床相关信息、改善沟通且未增加门诊时间。
- 患者报告体验总体未受影响(P=0.82),门诊协调领域正面回应概率随时间显著(P=0.025)。
核心结论
- MDASI-HN的实施被患者和提供者认为可行且可接受。
- 尽管患者报告体验总体未受实施影响,但部分方面随治疗进展有所改善。
研究设计与样本
- 前瞻性纵向研究,于2020年9月至2021年8月在三级癌症机构开展。
- 纳入新诊断头颈肿瘤、拟接受放疗伴或不伴化疗且能用英语交流的患者。
- 实施后队列51例患者入组,29例(60%)完成退出调查;5名头颈放疗提供者中4名(80%)完成退出调查。
- 次要结局为实施前后两个队列的简化Your Voice Matters调查(YVM)记录的患者报告体验及症状评分。
主要发现
- 89%患者报告MDASI-HN使其更容易记住症状,86%推荐在常规护理中使用。
- 75%提供者认为MDASI-HN提供临床相关信息、改善与患者沟通且未增加门诊时间。
- 患者报告体验总体未受实施影响(P=0.82)。
- 实施后队列在门诊协调领域正面回应概率随时间显著(P=0.025)。
关键数值与推荐
- 可行性及可接受性通过患者和提供者退出调查评估。
- 患者报告体验采用简化YVM调查在实施前后两个队列中记录。
- 症状评分采用描述性统计,YVM各问题正面回应差异采用Mann-Whitney检验,患者报告体验随时间变化采用Cochrane-Armitage检验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the feasibility and acceptability of implementing the MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) module in cancer clinics and its effect on patient-reported experience. METHODS: We conducted a prospective, longitudinal study at a tertiary cancer institution between September 2020 and August 2021. Patients with newly diagnosed head and neck (HN) cancer who were evaluated to receive radiation therapy with or without chemotherapy and could communicate in English were approached to participate. The primary outcome was feasibility and acceptability of the MDASI-HN implementation in the radiation oncology department assessed by patient and provider exit surveys. Secondary outcomes were patient-reported experience as recorded by a shortened Your Voice Matters survey (YVM) in 2 cohorts pre- and post-MDASI-HN implementation and symptom scores. Descriptive statistics were used for exit surveys and symptom scores. Mann-Whitney tests were used to assess differences in positive responses between pre- and postimplementation for each YVM question. Cochrane-Armitage tests were used to examine changes in patient-reported experience over time. RESULTS: Fifty-one patients were enrolled in the postimplementation cohort and 29 (60%) responded to the exit survey. Eighty-nine percent of patients reported that MDASI-HN made it easier to remember symptoms, and 86% recommend its use in routine care. Four of the 5 radiation oncology HN providers (80%) responded to exit surveys; 75% felt the MDASI-HN provided clinically relevant information, improved communication with patients, and did not increase clinic time. The overall patient-reported experience was not affected by the implementation (P = .82). The probability of positive responses over time was significant (P = .025) in the clinic coordination domain for the postimplementation cohort. CONCLUSIONS: Implementation of MDASI-HN was feasible and acceptable by patients and providers. Although the overall patient-reported experience was not affected by implementation, some aspects improved as treatment progressed.
引用
- Al-Rashdan A, Grendarova P, Yannitsos D, et al. Feasibility and Acceptability of Implementing Site-Specific Patient-Reported Outcome Measure in Head and Neck Cancer Clinics: A Prospective Institutional Study. Adv Radiat Oncol. 2022. PMID: 36420192. doi:10.1016/j.adro.2022.101036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。